

*B2*  
*complied*

8. (Once Amended) A composition as defined in claim 7, wherein said drug has a dose to aqueous solubility ratio greater than 100.

*B3* *and* *C4*

14. (Once Amended) A composition as defined in claim 11, wherein said drug has a dose to aqueous solubility ratio greater than 100.

*B4*

15. (Once Amended) A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion effecting, *in vivo*, an area under a curve (AUC) plotting the serum or plasma concentration of drug along the ordinate against time on the abscissa that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

*B5*

18. (Once Amended) A composition as defined in claim 15, wherein said drug has a dose to aqueous solubility ratio greater than 100.

*B6*


22. (Once Amended) A composition as defined in claim 1, wherein the concentration of drug in MFD solution falls to no less than 25% of the maximum supersaturated concentration during the 15 minutes following the time at which the maximum supersaturated concentration is reached.

*B7*

28. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is a glycogen phosphorylase inhibitor.


*B8*

29. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is



or a pharmaceutically acceptable salt thereof.


30. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is



or a pharmaceutically acceptable salt thereof.

31. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is a 5-lipoxygenase inhibitor.


32. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is



or a pharmaceutically acceptable salt thereof.

33. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is a corticotropin releasing hormone (CRH) inhibitor.

34. (Once Amended) A composition as defined in claims 1, 7, 11, or 15, wherein said drug is



or a pharmaceutically acceptable salt thereof.